Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

An Abstract Provides "seAFOod" for Thought.

Andrea DeCensi1, Andreas Gescher2

  • 1Ospedali Galliera, Genoa, Italy.

Cancer Prevention Research (Philadelphia, Pa.)
|February 1, 2019
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Automatic metabolic breast cancer staging using [¹⁸F]FDG PET/CT: comparison with nuclear medicine physician-based and clinical staging.

European journal of nuclear medicine and molecular imaging·2026
Same author

Low-Dose Tamoxifen in Noninvasive Breast Neoplasia: Long-Term Results From an Individual-Participant Data Pooled Analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

The Long and Winding Road toward Prevention of Estrogen Receptor-Negative and BRCA1-Associated Breast Cancer.

Cancer prevention research (Philadelphia, Pa.)·2026
Same author

European Code Against Cancer, 5th edition - organised cancer screening programmes.

Molecular oncology·2026
Same author

Efficacy and toxicity of low-doses versus standard-dose enzalutamide in advanced prostate cancer: a real-world study with implications for cancer prevention/interception.

BMC cancer·2025
Same author

Letrozole for hormone receptor-positive low-grade ovarian cancer: Preliminary toxicity results of a phase III trial.

Tumori·2025

Aspirin and eicosapentaenoic acid (EPA) show potential in preventing colorectal adenomas after resection, despite the seAFOod trial

Area of Science:

  • Gastroenterology
  • Oncology
  • Pharmacology

Background:

  • Colorectal adenomas are precursors to colorectal cancer.
  • Chemoprevention strategies are crucial for reducing adenoma recurrence.
  • The seAFOod trial investigated aspirin and eicosapentaenoic acid (EPA) for adenoma prevention.

Purpose of the Study:

  • To evaluate the chemopreventive efficacy of aspirin and EPA in patients with colorectal adenomas.
  • To highlight the importance of reporting secondary endpoints in clinical trial abstracts.

Main Methods:

  • Patients with colorectal adenomas underwent resection.
  • Post-resection treatment involved aspirin and/or eicosapentaenoic acid (EPA).
  • Adenoma detection rate and adenoma number were assessed as endpoints.

Related Experiment Videos

Main Results:

  • The primary endpoint, adenoma detection rate, was negative.
  • Significant reductions in adenoma number were observed, suggesting chemopreventive effects of both aspirin and EPA.
  • Secondary endpoint findings indicating efficacy were not highlighted in the original abstract.

Conclusions:

  • Aspirin and EPA demonstrate potential chemopreventive efficacy against colorectal adenomas.
  • Reporting secondary findings in abstracts is vital for comprehensive scientific communication.
  • Further research into these agents for colorectal cancer prevention is warranted.